China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
November 19, 2026SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main…
